MetaVia Inc. (MTVA) - Market Cap to Earnings
The prospects for MetaVia Inc (MTVA) depend on the long-term launch of new drug trials, while the speculative potential of the preclinical stage is already priced in. MetaVia Inc (MTVA) is building an image as a leading developer of methods to combat neuronal decay, transforming approaches to CNS therapy. Price action with the -0.70 indicator confirms the business's strong pricing power due to the creation of unique molecules capable of suppressing brain inflammation.
Comprehensive metric breakdowns and analytics for MetaVia Inc. (MTVA)
- stock value and consensus price forecast:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Equity MetaVia Inc|MTVA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient MetaVia, Inc.|MTVA - Company Aggregate Debts|Debts to Book Capitalization MetaVia Inc.|MTVA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings MetaVia|Interim Coverage Ratio metaviatx.com
- earnings and valuation multiples information:
MTVA - Company Net Income|Net Profit Forecast MetaVia Inc|MTVA - P/E Multiple|Projected Price to Earnings MetaVia, Inc.|MTVA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio MetaVia Inc.|MTVA - Operating profit before deduction of amortization|Earnings per share for the last four quarters MetaVia|MTVA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months metaviatx.com|MTVA - Earnings growth in current year|Earnings growth forecast for next year MetaVia Inc
Summary company analysis:MTVA, metaviatx.com
MetaVia Inc. innovations in the therapy of neurodegenerative diseases are driving high investment attractiveness, which is reflected in the company's estimated P/E ratio. This ratio compares market capitalization with net income, allowing for an assessment of the investment payback period and determining whether the asset is overvalued relative to its ability to generate real cash flow over the long term.
Competing companies
Price to Earnings Ratio biogen.com (BIIB)|P/E Multiple NBIX|RGC - Market Cap to Earnings|Axsome Therapeutics Inc - Price to Earnings Ratio|Market Price to Net Income Ratio ACAD (ACADIA Corp)|Xenon Pharmaceuticals - P/E Multiple|VKTX - P/E Multiple|SUPN (Supernus) - Price to Earnings Ratio|CPRX (Catalyst Pharma) - Price to Earnings Ratio|DNLI (Denali Therapeutics Inc) - P/E Multiple|Harmony Corp (HRMY) - Business Payback Period|P/E Multiple BHVN|P/E Multiple amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|Business Payback Period CeriBell EEG CBLL|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ALEC|ANNX (Annexon) - P/E Multiple|Price to Earnings Ratio Omeros Corp. (OMER)|Price to Earnings Ratio Neurogene Corp (NGNE)|Price to Earnings Ratio AC Immune Inc ACIU|Voyager Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio NMRA (neumoratx.com)|SCLX: Price to Earnings Ratio|TVGN: Price to Earnings Ratio|ACOG: P/E Multiple|Cognition Therapeutics Inc. (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Price to Earnings Multiple SAVA (cassavasciences.com)|P/E Multiple ASRT|COYA - Market Cap to Earnings|Vistagen - Price to Earnings Ratio|P/E Multiple Ovid Therapeutics Inc OVID|ABOS - Price to Earnings Ratio|Company Value to Net Income CRVO (cervomed.com)|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|Market Cap to Earnings Clene (CLNN)|Price to Earnings Ratio PepGen Inc|Price to Earnings Ratio Jupiter Neurosciences, Inc. (JUNS)|P/E Multiple RLMD|ANVS - Market Cap to Earnings|Grace Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio AIFF (Firefly Neuroscience, Inc.)|ANEW Medical, Inc. - P/E Multiple|NRSN - P/E Multiple|RVPH (Reviva Pharmaceuticals) - Price to Earnings Ratio|NRXS (neuraxis.com) - Price to Earnings Ratio|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Passage Bio Corp (PASG) - Business Payback Period|P/E Multiple NEUP|P/E Multiple Minerva (NERV)|Athira Pharma, Inc. - Price to Earnings Ratio|Company Value to Net Income ADXN|Alzamend - P/E Multiple|Business Payback Period Cyclerion Therapeutics CYCN|protagenic.com (PTIX) - Price to Earnings Ratio|Price to Earnings Multiple KTTA|CRGT (Cortigent Inc) - P/E Multiple|Price to Earnings Ratio avenuetx.com (ATXI)|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|Price to Earnings Ratio Cara Therapeutics Inc. CARA|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Market Price to Net Income Ratio ELYM (Eliem Therapeutics, Inc.)|ITCI: Price to Earnings Ratio|LBPH: Price to Earnings Ratio|MRNS: P/E Multiple|NKGen Biotech Inc (NKGN) - P/E Multiple|Price to Earnings Ratio NeuroBo|Price to Earnings Multiple SAGE (Sage Therapeutics Inc)|P/E Multiple SNPX|TRVN - Market Cap to Earnings|Vigil Neuroscience, Inc. - Price to Earnings Ratio|P/E Multiple anewmeds.com WENA|CERE - Price to Earnings Ratio
